MSN Laboratories announced the launch of branded generic favipiravir, Favilow 800 mg. The higher strength Favilow 800 mg is priced at Rs 144 per tablet and will be available across pharmacies.
The field team of MSN Labs is also helping out with free home delivery in over 170 cities in coordination with local retail chemists, informed the company.
Dr MSN Reddy, CMD, MSN Group said, “In the light of increasing C-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation’s efforts in overcoming the C-19 crisis.”
MSN had launched the branded generic of Favipiravir, Favilow, in August last year, in the strengths of 200 and 400 mg. MSN claims the higher strength will improve patient compliance and experience by effectively reducing the number of tablets a patient requires per day.
Bharat Reddy, Executive Director – MSN Group added, “MSN is currently manufacturing more than 1 lac dosage regimen (5 lakh *strips of different strengths of FAVILOW) for the treatment of C-19 in last 15 days, and are scaling up the manufacturing volumes to 6-8 lacs dosage regimen (30 lakh strips of different strengths of FAVILOW) by next month.”
The higher strength of Favipiravir 800 mg from MSN has been approved by the Drug Controller General of India (DCGI). MSN developed the active pharmaceutical ingredient (API) and the formulation for FAVILOW 800 mg in its in-house R&D and manufacturing units.
As part of the C-19 treatment range, MSN has launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ‘OSELOW’.
Also read:
Gilead announces steps to expand availability of Remdesivir in India
Drug alert: 18 out of 1571 samples declared as NSQ in March 2021
IPC starts verifying testing protocols for DCGI approved drugs
IMA urges PM to make vaccine affordable through Jan Aushadhi stores
NATCO applies to CDSCO for EUA of Molnupiravir capsule
